These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 21552209)

  • 1. Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas.
    Hong SM; Li A; Olino K; Wolfgang CL; Herman JM; Schulick RD; Iacobuzio-Donahue C; Hruban RH; Goggins M
    Mod Pathol; 2011 Sep; 24(9):1237-47. PubMed ID: 21552209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival.
    Lee SH; Kim H; Hwang JH; Shin E; Lee HS; Hwang DW; Cho JY; Yoon YS; Han HS; Cha BH
    Pancreas; 2014 Apr; 43(3):380-8. PubMed ID: 24622067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma.
    Foo WC; Rashid A; Wang H; Katz MH; Lee JE; Pisters PW; Wolff RA; Abbruzzese JL; Fleming JB; Wang H
    Hum Pathol; 2013 Jun; 44(6):1024-30. PubMed ID: 23260327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases.
    Cao D; Zhang Q; Wu LS; Salaria SN; Winter JW; Hruban RH; Goggins MS; Abbruzzese JL; Maitra A; Ho L
    Mod Pathol; 2007 May; 20(5):570-8. PubMed ID: 17396143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients.
    Guo S; Jing W; Hu X; Zhou X; Liu L; Zhu M; Yin F; Chen R; Zhao J; Guo Y
    Int J Cancer; 2014 Mar; 134(6):1369-78. PubMed ID: 24037692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
    BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma.
    Denley SM; Jamieson NB; McCall P; Oien KA; Morton JP; Carter CR; Edwards J; McKay CJ
    J Gastrointest Surg; 2013 May; 17(5):887-98. PubMed ID: 23435739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma.
    Wang L; Gu F; Ma N; Zhang L; Bian JM; Cao HY
    Tumour Biol; 2013 Aug; 34(4):2309-13. PubMed ID: 23568706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients.
    Lee SH; Kim H; Hwang JH; Lee HS; Cho JY; Yoon YS; Han HS
    Pathol Int; 2012 Mar; 62(3):167-75. PubMed ID: 22360504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High vimentin expression with E-cadherin expression loss predicts a poor prognosis after resection of grade 1 and 2 pancreatic neuroendocrine tumors.
    Zhou B; Xiang J; Jin M; Zheng X; Li G; Yan S
    BMC Cancer; 2021 Mar; 21(1):334. PubMed ID: 33789624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR expression in pancreatic adenocarcinoma. Relationship to tumour morphology and cell adhesion proteins.
    Handra-Luca A; Hammel P; Sauvanet A; Lesty C; Ruszniewski P; Couvelard A
    J Clin Pathol; 2014 Apr; 67(4):295-300. PubMed ID: 24170210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas.
    Handra-Luca A; Hong SM; Walter K; Wolfgang C; Hruban R; Goggins M
    Br J Cancer; 2011 Apr; 104(8):1296-302. PubMed ID: 21448168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept.
    Martinez-Useros J; Georgiev-Hristov T; Fernández-Aceñero MJ; Borrero-Palacios A; Indacochea A; Guerrero S; Li W; Cebrián A; Gómez Del Pulgar T; Puime-Otin A; Del Puerto-Nevado L; Rodríguez-Remírez M; Pérez N; Celdrán A; Gebauer F; Garcia-Foncillas J
    PLoS One; 2017; 12(8):e0182044. PubMed ID: 28763470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anterior gradient 2 and mucin 4 expression mirrors tumor cell differentiation in pancreatic adenocarcinomas, but aberrant anterior gradient 2 expression predicts worse patient outcome in poorly differentiated tumors.
    Brychtova V; Hermanova M; Karasek P; Lenz J; Selingerova I; Vojtesek B; Kala Z; Hrstka R
    Pancreas; 2014 Jan; 43(1):75-81. PubMed ID: 24177142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma.
    Jamieson NB; Morran DC; Morton JP; Ali A; Dickson EJ; Carter CR; Sansom OJ; Evans TR; McKay CJ; Oien KA
    Clin Cancer Res; 2012 Jan; 18(2):534-45. PubMed ID: 22114136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma.
    Nagao Y; Hisaoka M; Matsuyama A; Kanemitsu S; Hamada T; Fukuyama T; Nakano R; Uchiyama A; Kawamoto M; Yamaguchi K; Hashimoto H
    Mod Pathol; 2012 Jan; 25(1):112-21. PubMed ID: 21983937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of SMAD4 staining in pre-operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancer.
    Boone BA; Sabbaghian S; Zenati M; Marsh JW; Moser AJ; Zureikat AH; Singhi AD; Zeh HJ; Krasinskas AM
    J Surg Oncol; 2014 Aug; 110(2):171-5. PubMed ID: 24665063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical expression of NEDD9, E-cadherin and γ-catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC).
    Radulović P; Krušlin B
    Bosn J Basic Med Sci; 2018 Aug; 18(3):246-251. PubMed ID: 29924959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.
    Richter A; Niedergethmann M; Sturm JW; Lorenz D; Post S; Trede M
    World J Surg; 2003 Mar; 27(3):324-9. PubMed ID: 12607060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer.
    Matsubayashi H; Infante JR; Winter J; Klein AP; Schulick R; Hruban R; Visvanathan K; Goggins M
    Cancer Biol Ther; 2007 Oct; 6(10):1569-75. PubMed ID: 18000398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.